** Shares of drugmaker TG Therapeutics TGTX.O rise 15.7% to $34.82
** Co posts Q4 net product revenue of $107.3 million, beating analysts' average estimate of $99.98 million - data compiled by LSEG
** TGTX's Q4 U.S. net product revenue for relapsing multiple sclerosis drug Briumvi came in at $103.6 million
** Co forecasts 2025 total revenue of about $540 million, compared with estimates of $548.2 million
** TGTX rose 71% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.